Abstract: With the advent of technology, as there seems to be no reason not to implement a trial with a continuous domain of doses and varying step sizes, we provide a non-parametric methodology for such trials that aims to estimate Maximum Tolerated Dose (MTD) in the phase I clinical trials. We further provide extensive simulations for logistic and probit model with various parameter values to obtain a pseudo sample size for better design of the trials. We also illustrate a bootstrap method to obtain an estimate of the variance and the bias of our estimator.
Introduction
Dose-response design and studies are conducted in phase I clinical trials to study toxicity in the drug development process. Sequential response-driven designs are usually carried out for this purpose. The patients are sequentially assigned to various dose levels of a drug, one or a group at a time, starting with the lowest dose. Then it proceeds by increasing or decreasing the dose level, or keeping it the same, depending on the particular design followed in the experiment. Skipping a dose is usually not allowed for ethical reason (see Faries, 1994 ). The goal is to find a dose level, x α , say, which has a prescribed probability, α, of toxic response, where the responses are binary (toxic/nontoxic). This dose is often referred to as the maximum tolerated dose (MTD). Usually, the specified value of α lies between 0 and 0.5; in phase I trials for oncology, α is usually taken between 0.2 and 0.3. For non-fatal diseases the α is much smaller. The MTD is commonly estimated by determining the most acceptable dose from a pre-specified set of k increasing dose levels x 1 < · · · < x k (See, for example, Dixon and Mood, 1954 , and, more recently, Storer, 1989) . Bueon et al. (2005) recently reviewed designs that have been used in some major studies since 1995.
Using the discreteness of the dose space, one group of designs, called up-and-down design, employs a Markovian technique to move up or down by one level, or stay at the same level, to eventually converge to the estimated MTD. See, for example, Durham and Flournoy (1995), , Giovagnoli and Pintacuda (1998) and Bortot and Giovagnoli (2005) . Note that these designs are essentially nonparametric in nature.
There have been few other nonparamteric designs based on the isotonic estimate of the dose response relationship, usually called isotonic designs. See, for example, Leung and Leung and Wang (2002) and Cheung and Chappel (2002) . Another Bayesian design, given by Babb et al. (1998) , uses a loss function to minimize the predicted amount by which any given patient is overdosed. Some other Bayesian designs are described in McLeish and Tosh (1990) , Whitehead and Brunier (1995) and Whitehead and Williamson (1998) . Now-a-days, with the advent of technology, there seems to be no reason why a trial cannot be implemented with a continuous domain of dose and varying step sizes. The estimation of MTD in such case can be made more accurate. Mats et al. (1998) have considered a continuous dose space for the purpose of finding locally optimal designs to estimate MTD assuming a general class of parametric dose response models including logistic, probit, complementary log-log, etc.. According to their findings, the support points of the optimal designs may not be contained in the considered dose levels if they form a finite lattice. Rosenberger et al. (2001) have considered a similar problem in the Bayesian context, while Liu et al. (2006) have studied sequential designs for logistic dose response model for both continuous and discrete dose spaces. Storer (1989 Storer ( , 1993 has considered logistic dose response model with discrete dose space to estimate the model parameters which are then used to estimate the MTD; this estimate may not be one of the considered dose levels. Li et al. (1995) have discussed the possibility of continuous dose space in the context of phase II trial assuming some parametric models.
In the present paper, we propose a method of estimating MTD with continuous domain of dose and variable step size using a procedure similar to Robbins and Monro (1951) without making any particular parametric assumption for the dose response model. We also demonstrate by means of a simulation study that, using variable step size, the estimated MTD can be very close to the true value, so that some efficiency can be achieved in the subsequent phase II trial. In practice, this procedure takes bigger step size at the beginning while tapering down gradually. In order to achieve nearness to the target dose faster, we calibrate the step size with a number of, say k, previous responses by making it dependent on the number of similar responses; see the next section for details.
The rest of the paper is organized as follows. In Section 2, we discuss our methodology. Section 3 describes some performance characteristics which are examined through a simulation study in Section 4. Section 5 ends with some concluding remarks.
Methodology
Let Y be the binary response variable representing the toxic response of interest due to application of a drug at a certain dose with Y = 1 meaning the toxic response. Let P (x) be the probability of toxic response at dose X = x; that is,
For a given α lying between 0 and 1, the objective is to find the MTD x α such that P (x α ) = α with the form of P (·) being unknown.
Let x
* be a level of dose which, from previous studies or animal trials, is known to be highly toxic. In practice, x * is greater than x α . Ideally, this x * should be chosen as close to x α as possible. We assume x * to be, say, the qth percentile of P (x). It is sufficient to know x * , although it helps to have information on q as well. At present, we do not use any information on q; but knowledge of x * will be used. We assume that the participants are subjected to the drug sequentially at different doses (chosen adaptively depending on the previous doses and responses). Let x i be the dose for the ith participant, for i = 1, · · · , n, where n, the number of participants, is considered fixed in advance for the time. Although, in practice, there is a limit on the number of patients, n, we shall see later that n need not be fixed in advance and a reasonable stopping rule can be deviced to end the trial. It is a good idea to choose x 1 , dose of the first participant, in the neighbourhood of x α ; however, since x α is not known, we suggest choosing x 1 , from our previous knowledge on animal trials, etc., in such a way that it provides a small risk of toxic response. If no such information is available, one may choose x 1 = 0 conservatively.
A generalization of Robbins-Monro (1951) procedure suggests the following adaptive formula for x i+1 , for i = 1, · · · , n:
where y i is the observed value of Y for the ith participant, a i 's are positive constants such that Joseph, 2004) , and C i 's are some bounded positive constants as described below. Under such conditions, this procedure has been proved to be consistent in the sense that the resulting estimate converges to the true MTD in probability as n → ∞.
Initially, we take C i = C for i = 1, · · · , k, where k (=5, say) is a suitably chosen integer. This constant C represents the length of jump in successive dose levels in either direction, modulated by a i , for the first k participants. The idea is to observe and note the trend of recent k changes in dose level to make a decision about the next dose level.
Then, for i > k, depending on the trend in the last k dose levels, the next jump length is determined as a multiple of C (to preserve the unit of dose measurements), given by
where
That is, if the successive dose levels (for the recent k participants) either increase or decrease (corresponding to non-toxic or toxic responses, respectively), the δ i will be k (the largest value) leading to a big jump; on the other hand, if there are several direction changes in dose levels (for the recent k participants), the δ i will be smaller (at least being 0) leading to a small jump. In order to choose a value of C, we make the assumption that if, theoretically, starting with x 1 , all the n * responses (with a suitably chosen n * satisfying some optimality criterion) are non-toxic, the selected dose level for the (n * + 1)st participant will be x * . Then, from (1), we have
This gives us
Since x 1 is chosen conservatively and x * is chosen to have high probability of toxic response, we always have x * > x 1 and, hence, C > 0. The pseudo sample size n * is chosen in an optimal manner in some sense, as described in the following. It is to be noted that the value of C, hence the successive jump lengths, decreases as n * increases leading to possible under-estimation. Therefore, larger value of n * makes the estimate more conservative, whereas smaller value of n * , leading to larger jump lengths, runs the risk of over-estimation. In practice, since there may be both toxic and non-toxic responses, larger jump lengths (due to smaller n * ) lead to more variance and, on the other hand, smaller jump lengths (due to larger n * ) lead to more bias. We see this pattern in our simulation study also. Table  1 , the 'optimal' (see the next paragraph and also Section 4) n * lies between 40 and 75; therefore, the figure in the middle panel corresponds to a proper choice of n * . We suggest finding the 'optimal' value of n * by minimizing the mean squared error (MSE) of the estimated x α . The 'optimal' value of n * may depend on the parameters of the dose response curve (such as, intercept and slope) in addition to the values of α and q. It is seen, by means of an extensive simulation study in Section 4, that the dependence of 'optimal' value of n * on q and the slope parameter is rather weak. We give, in Table  1 , a guideline for the choice of 'optimal' n * , for different values of α, q, intercept and slope of P (x), which minimizes the corresponding estimated MSE. The experimenter is likely to have some idea about the intercept parameter, from previous studies or animal trials, to help in choosing n * from our guideline, for a given α. Once the constant C is chosen, as a function of n * , x 1 , x * and α, the adaptive procedure of determining the successive dose levels for the n participants can be carried out using (1) . The final dose x n+1 can be taken as an estimate of x α . We, however, suggest the mean of the last m dose levels (that is, x n−m+2 , · · · , x n+1 ) as an estimate of x α , for some suitably chosen m, to reduce the variability. Let us denote this estimate bŷ
In order to obtain an estimate of the variance of this estimate, we suggest a bootstrap sampling method as described in the following. Using the observed values of the dose levels x 1 , · · · , x n and the corresponding responses y 1 , · · · , y n , we find a smooth parametric estimate of the dose response curve P (x) by assuming a specific model, say, logistic.
The difficulty lies in the fact that the successive x i 's are not independent. Therefore, the estimated P (x), denoted byP (x), can be considered to be an approximation to be used only for the purpose of bootstrap sampling. For each bootstrap sample, say the bth, we start with x b1 = x 1 and simulate y b1 from the Bernoulli distribution with success probabilityP (x b1 ). Then, choose the successive bootstrap dose levels by using the formula, similar to (1),
Then, the bth bootstrap estimate of x α is given by the mean of
, which is denoted byx bα . We carry out this bootstrap sampling The left, middle and right panels correspond to n * = 125, 50 and 20, respectively.
Some Performance Characteristics
Although the objective of this work is to estimate the MTD, x α , using continuous dose regimen and variable step size, as closely as possible to the true value, it should not be at the cost of too many adverse toxic responses during the trial. The idea is to be able to estimate MTD from below rather than moving back and forth on either side of the true value. The construction of the C i 's, as in (2), representing the variable step size, and the algorithm for updating the dose, given by (1), have been suggested to minimize this 'loss' due to likely toxic responses at the selected dose levels above the MTD. The purpose of this section is to introduce some performance characteristics in terms of which this particular behavior of our methodology can be studied.
One standard choice is bias, given by E[x α − x α ]. Ideally, we like this to be zero; if not, this should be negative so that the estimate is conservative (that is, not an overestimate). Along with bias, we also consider variance and MSE ofx α and like them to be small as a mark of good performance.
One natural choice to measure the performance of our methodology is the expected proportion of toxic responses out of the n observations, denoted by P T OX. In order to be ethically proper, we like this P T OX to be small. The next one is the expected proportion of selected dose levels (excluding x 1 ) which are larger than the MTD, x α .
Let us denote this by P ROP , which we also like to be small. We also consider the average (over the n observations) of the expected amount of overdoses, (x i − x α )'s, given x i ≥ x α , and denote it by MDIF F . We like this to be small to ensure that, even if we select a dose larger than x α , it is not too large. In practice, however, we are more concerned with the expected additional risk of toxicity associated with a dose larger than x α , rather than the actual dose difference. Therefore, we consider P DIF F , the average of the probability differences, (P (x i ) − α)'s (additional risk), for those dose levels which are larger than x α . We like this average additional risk to be small as well.
Formally, these four characteristics can be written as
, and
where Y i denotes the random variable representing the response of the ith participant, for i = 1, · · · , n, and X i represents the ith selected dose, for i = 2, · · · , n + 1. These quantities may be derived in theory in terms of the unknown dose response function P (x). This derivation, however, becomes increasingly difficult with large n because of the complicated dependence structure among the selected doses X i 's and the responses Y i 's. Nevertheless, based on one simulated sample with known x α and dose response P (·), these can be readily estimated as
The averages of these estimates over a number of simulated samples can be taken as the estimates of the corresponding quantities, as reported in the next section.
A Simulation Study
In our simulation study, we assess the properties of the suggested estimate of x α , developed in Section 2, in terms of the performance characteristics described in the previous section. We consider both logistic and probit dose response model for P (x), given by One simulation run starts with x 1 = max(0, x ǫ ), where x ǫ denotes the ǫth percentile of the dose response curve, with ǫ = 0.01. This is to reflect the choice that information about the minimum risk, say ǫ, leads to x 1 = x ǫ and no information leads to x 1 = 0. We generate the response variables Y i 's from a Bernoulli trial with probability of success P (x i ) and obtain the subsequent dose levels x i+1 's using the formula (1), for i = 1, · · · , n, with n = 30, 50 and 100. In order to obtain the successive jump lengths, we derive C using (3) with n * given by [nw] , where [x] denotes the largest integer less than or equal to x. We take w = 0.05, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 1.1, 1.2, 1.3, 1.4, 1.5, 2.0 for our simulation study to investigate which value of n * leads to minimum estimated MSE.
We carry out 1000 such simulation runs for a fixed set of parameters (a, b), values of α, q, sample size (n) and w. For each simulation run, we recordx α , the estimate of x α , as described in Section 2. Since computation of variance estimate ofx α by bootstrap sampling method (see Section 2) is somewhat extensive, we do not perform this task for all values of w in our simulation study. Instead, we adopt the following strategy. We first estimate the mean and variance ofx α by the average and sample variance based on the 1000 estimates,x α 's, from the 1000 simulation runs. This leads to estimates of bias and MSE ofx α based on simulation. For a fixed set of dose response parameters (a, b), values of α, q and sample size n, we identify the value of w, or n * , that gives the minimum value of estimated MSE ofx α . The bias-variance trade-off, as discussed in Section 2, gives such a minimum value. However, in order to deal with the sampling variation, we consider all those values of w, or n * , which lead to values of estimated MSE within 10% of the minimum estimated MSE (treating them as 'plausibly optimal' values of n * ). Then, we take the mid-value of these n * values to be considered as the 'optimal' value of n * . In Table 1 , we present this range of 'plausibly optimal' n * values for different values of α, q, (a, b) and n, and for both logistic and probit model, to be considered as a guideline for choosing n * . Since larger value of n * leads to conservative estimate (as discussed in Section 2), one may want to choose the largest one from this range.
The 'plausibly optimal' n * values seem to depend weakly on n and, in general, there is an increasing trend with n. Since larger value of n * means smaller jump, this increasing trend with n makes the method more meaningful. The dependence of the 'plausibly optimal' n * values on α is strong, as expected. But the dependence on q is not so strong; this is desirable as the practitioners often choose the value of x * , for a particular value of q, from the previous experience. Another desirable outcome is that the dependence on the slope (b) is apparently weak; the practitioners often will not have any information on b. There seems to be some dependence on the intercept (a); the case with a = −2 giving larger values for 'plausibly optimal' n * . Therefore, when there is higher background response probability, the jump size is smaller; this is a desirable feature acting as a safeguard against possible over-estimation. Often, based on prior information or experimental data, there may be some information on the background response probability, or intercept a. The logit and probit models seem to give similar values, except for the case with a = −2 (that is, when the background response probability is relatively high).
This background response probability is about 12% for logit model and about 2% for probit model. Based on the prior information on the background response probability, as mentioned before, one may be able to choose one model from the other for the purpose of selecting the 'plausibly optimal' n * values. It may be noted that the logit model giving higher background response probability (with a = −2) also desirably leads to larger values of 'plausibly optimal' n * . In general, when the background response probability is not high (a = −5 or -10), the dependence of the 'plausibly optimal' n * values on the other parameters (except α) is rather weak, giving the methodology more flexibility. The next phase of the simulation study considers only the optimal n * , as discussed before. For each simulation run, we obtainx α along with its bias and variance estimate by a bootstrap sampling method, as discussed in Section 2, with B = 200 bootstrap samples. We also record P T OX, P ROP , MDIF F and P DIF F , as described in Section 3. We then take averages of these quantities over the 1000 simulation runs. The sample variances of the last four quantities are also computed. The bias and variance ofx α are also estimated based on the sample of 1000 estimates of x α . The averages of the bootstrap estimates of bias and variance over the 1000 simulation runs tend to be lower than the corresponding sample versions and the difference reduces with increasing sample size (n). While the mean of the bootstrap estimates of bias is much lower than the sample estimates, the corresponding variance estimate is lower by a factor, generally ranging between 0.6 to 1.0. Also, as remarked in Section 2, about 80 to 90% of the 1000 bootstrap estimates of the variance, depending on the sample size, tend to be smaller than the corresponding sample versions.
In Tables 2a, b and 3a, b for logit and probit models, respectively, we present the simulation based estimates of the quantities x α , P T OX, P ROP , MDIF F and P DIF F , along with the corresponding standard errors in parentheses. The standard error of . Estimated performance characteristics with the optimal n * for the logit model with a = −5. . Estimated performance characteristics with the optimal n * for the probit model with a = −2. . Estimated performance characteristics with the optimal n * for the probit model with a = −5. Note that the proposedx α under-estimates x α , a desirable feature while estimating the MTD. The negative bias and the corresponding standard error tend to be lower in magnitude with increasing sample size, as expected. The magnitude of bias and the corresponding standard error seem to be little affected by the choice of q, which is also a desirable feature. Whatever little difference exists for the different choices of q seems to disappear when mean squared error is considered. Generally, about 12 to 25% of the responses are toxic (given by P T OX). Again, about 10 to 30% of the selected doses happen to exceed the true MTD (given by P ROP ). The amount of overdose (given by MDIF F ) generally does not reach beyond 30% of the true MTD, but often is as low as 3-4% above the MTD. This amount of overdose generally decreases with n. The additional risk (given by P DIF F ) is also generally small, often lying within 5%.
Concluding Remarks
The main feature of this paper is the model-free approach for estimation of maximum tolerated dose (MTD) in the context of phase I clinical trials with a continuous domain of dose and variable step size using a generalization of Robbins-Monro (1951) procedure.
The step sizes are chosen adaptively by incorporating a larger amount of information (that can be fixed, as given by k in (2), by the user) than only the previous response, as is usually done. The method is quick to produce the next updated dose using as much information as deemed suitable and, in principle, may vary at each step by changing the value of k. A desirable outcome is the apparent under-estimation of MTD. The suggested bootstrap variance estimate also seems to be an under-estimate, but the extent of under-estimation is limited to about 60% and reduces with increasing sample size.
This, however, leads to conservative estimation of MTD. Derivation of standard error for the estimate of MTD in this context has generally not been attempted, which is another added feature of our method.
In order to apply the method, as described in Section 2, one needs to have some information on x 1 , the starting dose, x * , a highly toxic dose and n * , to be chosen optimally in some sense. Intuitively, choice of x 1 may not have much impact if the sample size n is sufficiently large. In practice, we have little control over the choice except insisting that it be close to x α , or choose x 1 = 0 conservatively. Choice of x * and optimal n * are related to each other. We have expressed x * as the qth percentile of the dose response curve and studied the impact of this choice through q in Section 4. As remarked in the previous section, the estimate of MTD and the corresponding standard error seem to be quite robust against the two choices of q (see Tables 2a , b and 3a, b) . The choice of optimal n * seems to be very important. Table 1 gives a guideline for this choice. It is seen there that this choice depends weakly on q and the slope of the dose response curve; however, there seems to be some dependence on the intercept. It is likely to have some information on the background response giving some idea about the choice of n * from Table 1 ; this information also helps in the choice of x 1 .
Note that, once the optimal n * is chosen resulting in the value of C, the adaptive procedure of updating the next dose level proceeds without any reference to the sample size n. Therefore, the method does not have to stop at nth participant and, as a matter of fact, the updating can be continued till a suitable stopping rule. This stopping rule may be in terms achieving some pre-assigned bias and/or precision which are seen to improve with sample size. In application, after few responses are obtained, one can simulate the trial with an assumed dose response curve and make an assessment of the required sample size for given bias and precision.
The present approach can be implemented adaptively to a more general set up where, after a few patients are observed, the experimenter decides to change the value of α. The already available data can be used to estimate the dose response curve, which can be used to choose the new values of x 1 and x * (and, hence, C) corresponding to the new α to suggest a procedure similar to (1) for the subsequent patients. The details are under study.
